This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Julia R. Howard-Williams, MD; Marc J. Siegel, MD; Steven M. Podos, MD; Virgil Brown, MD
New York

Arch Ophthalmol. 1986;104(4):488-490.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Platelet hypersensitivity and increased prostaglandin levels have been implicated in the development of diabetic retinopathy.¹ Dipyridamole is an inhibitor of thromboxane A₂ synthesis and platelet aggregation. Microangiopathy and a breakdown of the blood-retinal barrier have been correlated with fluorescein leakage into the posterior vitreous.² We have studied the effect of dipyridamole on the blood-retinal barrier of patients with diabetes mellitus by vitreous fluorophotometry.

Patients and Methods.

—Forty maturity-onset diabetic patients with background retinopathy were recruited from the medical diabetic clinic at Mount Sinai Hospital, New York. The patients underwent a general physical and ophthalmic examination, including gonioscopy and fundus photography. Excluded from the study were brittle diabetics, women of childbearing potential, hypertensive subjects with diastolic blood pressures greater than 100 mm Hg while on medication, and patients with proliferative retinopathy, previous photocoagulation therapy, or opaque media. Also excluded were patients taking the following medications: . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?